{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:14:27Z","timestamp":1790709267308,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Academic Thesis Research Fund (ATRF) committee, Faculty of Pharmacy, Alexandria university.","award":["ATRF-319014"],"award-info":[{"award-number":["ATRF-319014"]}]},{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fisetin (FIS) is a multifunctional bioactive flavanol that has been recently exploited as anticancer drug against various cancers including breast cancer. However, its poor aqueous solubility has constrained its clinical application. In the current work, fisetin is complexed for the first time with soy phosphatidylcholine in the presence of cholesterol to form a novel biocompatible phytosomal system entitled \u201ccholephytosomes.\u201d To improve fisetin antitumor activity against breast cancer, stearylamine bearing cationic cholephytosomes (mPHY) were prepared and furtherly modified with hyaluronic acid (HPHY) to allow their orientation to cancer cells through their surface exposed phosphatidylserine and CD-44 receptors, respectively. In vitro characterization studies revealed promising physicochemical properties of both modified vesicles (mPHY and HPHY) including excellent FIS complexation efficiency (\u02f7100%), improved octanol\/water solubility along with a sustained drug release over 24\u00a0h. In vitro cell line studies against MDA-MB-231 cell line showed about 10- and 3.5-fold inhibition in IC50 of modified vesicles compared with free drug and conventional drug-phospholipid complex, respectively. Preclinical studies revealed that both modified cholephytosomes (mPHY and HPHY) had comparable cytotoxicity that is significantly surpassing free drug cytotoxicity. TGF-\u03b21and its non-canonical related signaling pathway; ERK1\/2, NF-\u03baB, and MMP-9 were involved in halting tumorigenesis. Thus, tailoring novel phytosomal nanosystems for FIS could open opportunity for its clinical utility against cancer.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-023-01409-5","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:01:45Z","timestamp":1693353705000},"page":"433-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: in vitro appraisal and in vivo antitumoral studies"],"prefix":"10.1007","volume":"14","author":[{"given":"Sara M.","family":"Talaat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6939-7777","authenticated-orcid":false,"given":"Yosra S. R.","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mennatallah A.","family":"Gowayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar O.","family":"El-Ganainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossama Y.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"issue":"3","key":"1409_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1409_CR2","doi-asserted-by":"publisher","unstructured":"Harbeck N, et al.\u00a0\u201cBreast cancer\". Nat Rev Dis Prim. 2019;5(1).\u00a0https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","DOI":"10.1038\/s41572-019-0111-2"},{"key":"1409_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.actbio.2019.06.051","volume":"96","author":"W Li","year":"2019","unstructured":"Li W, et al. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency. Acta Biomater. 2019;96:456\u201367. https:\/\/doi.org\/10.1016\/j.actbio.2019.06.051.","journal-title":"Acta Biomater"},{"key":"1409_CR4","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.biopha.2018.07.079","volume":"106","author":"P Mehta","year":"2018","unstructured":"Mehta P, Pawar A, Mahadik K, Bothiraja C. Emerging novel drug delivery strategies for bioactive flavonol fisetin in biomedicine. Biomed Pharmacother. 2018;106:1282\u201391. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.079.","journal-title":"Biomed Pharmacother"},{"key":"1409_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.biopha.2017.10.164","volume":"97","author":"K Sundarraj","year":"2018","unstructured":"Sundarraj K, Raghunath A, Perumal E. A review on the chemotherapeutic potential of fisetin: in vitro evidences. Biomed Pharmacother. 2018;97:928\u201340. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.164.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"1409_CR6","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jcb.25490","volume":"117","author":"ML Smith","year":"2016","unstructured":"Smith ML, Murphy K, Doucette CD, Greenshields AL, Hoskin DW. The dietary flavonoid fisetin causes cell cycle arrest, caspase-dependent apoptosis, and enhanced cytotoxicity of chemotherapeutic drugs in triple-negative breast cancer Cells. J Cell Biochem. 2016;117(8):1913\u201325. https:\/\/doi.org\/10.1002\/jcb.25490.","journal-title":"J Cell Biochem"},{"issue":"2","key":"1409_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3892\/ijo.2011.1203","volume":"40","author":"PM Yang","year":"2012","unstructured":"Yang PM, Tseng HH, Peng CW, Chen WS, Chiu SJ. Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagy. Int J Oncol. 2012;40(2):469\u201378. https:\/\/doi.org\/10.3892\/ijo.2011.1203.","journal-title":"Int J Oncol"},{"key":"1409_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tifs.2017.10.003","volume":"70","author":"AF Naeimi","year":"2017","unstructured":"Naeimi AF, Alizadeh M. Antioxidant properties of the flavonoid fisetin: an updated review of in vivo and in vitro studies. Trends Food Sci Technol. 2017;70:34\u201344. https:\/\/doi.org\/10.1016\/j.tifs.2017.10.003.","journal-title":"Trends Food Sci Technol"},{"key":"1409_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lfs.2017.12.005","volume":"194","author":"D Kashyap","year":"2018","unstructured":"Kashyap D, Sharma A, Sak K, Tuli HS, Buttar HS, Bishayee A. Fisetin: a bioactive phytochemical with potential for cancer prevention and pharmacotherapy. Life Sci. 2018;194:75\u201387. https:\/\/doi.org\/10.1016\/j.lfs.2017.12.005.","journal-title":"Life Sci"},{"key":"1409_CR10","doi-asserted-by":"publisher","unstructured":"Lall RK, Adhami VM, Mukhtar H. \u201cDietary flavonoid fisetin for cancer prevention\u201d. 2016:1396\u20131405. https:\/\/doi.org\/10.1002\/mnfr.201600025.","DOI":"10.1002\/mnfr.201600025"},{"key":"1409_CR11","doi-asserted-by":"publisher","unstructured":"Syed DN, Adhami VM, Khan N, Khan MI, Mukhtar H. \u201cExploring the molecular targets of dietary flavonoid fisetin in cancer\u201d. Semin Cancer Biol. 2016;40_41:130\u2013140. https:\/\/doi.org\/10.1016\/j.semcancer.2016.04.003.","DOI":"10.1016\/j.semcancer.2016.04.003"},{"issue":"1\u20132","key":"1409_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2013.01.050","volume":"444","author":"J Seguin","year":"2013","unstructured":"Seguin J, et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm. 2013;444(1\u20132):146\u201354. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.01.050.","journal-title":"Int J Pharm"},{"issue":"1","key":"1409_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1517\/17425247.2013.860131","volume":"11","author":"C Bothiraja","year":"2014","unstructured":"Bothiraja C, Yojana BD, Pawar AP. Fisetin-loaded nanocochleates\u202f: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study. Expert Opin Drug Deliv. 2014;11(1):17\u201329.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"1409_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11095-016-2077-z","volume":"34","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang DZ, Wang Y. Bioflavonoid fisetin loaded \u03b1-tocopherol-poly(lactic acid)-based polymeric micelles.pdf. Pharm Res. 2017;34(2):453\u201361.","journal-title":"Pharm Res"},{"issue":"2","key":"1409_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijpharm.2012.02.025","volume":"427","author":"H Ragelle","year":"2012","unstructured":"Ragelle H, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm. 2012;427(2):452\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.02.025.","journal-title":"Int J Pharm"},{"issue":"46","key":"1409_CR16","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.1039\/c4ce01713g","volume":"16","author":"M Sowa","year":"2014","unstructured":"Sowa M, \u015alepokura K, Matczak-Jon E. Improving solubility of fisetin by cocrystallization \u2020. CrystEngComm. 2014;16(46):10592\u2013601. https:\/\/doi.org\/10.1039\/c4ce01713g.","journal-title":"CrystEngComm"},{"issue":"1","key":"1409_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/10717544.2016.1245366","volume":"24","author":"A Kadari","year":"2017","unstructured":"Kadari A, et al. Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HP \u03b2 CD in polymeric nanoparticles enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HP b. Drug Deliv. 2017;24(1):224\u201332. https:\/\/doi.org\/10.1080\/10717544.2016.1245366.","journal-title":"Drug Deliv"},{"key":"1409_CR18","doi-asserted-by":"crossref","unstructured":"Pawar A, Singh S, Rajalakshmi S, Shaikh K, Bothiraja C.\u00a0\u201cDevelopment of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting\u201d. Artif cell Nanomed Biotechnol. 2018;46(sup1)347\u2013361.","DOI":"10.1080\/21691401.2018.1423991"},{"key":"1409_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1872211312666180105114644","volume":"12","author":"V Agarwal","year":"2018","unstructured":"Agarwal V, Bajpai M, Sharma A. Patented and approval scenario of nanopharmaceuticals with relevancy to biomedical application, manufacturing procedure and safety aspects. Recent Pat Drug Deliv Formul. 2018;12:40\u201352. https:\/\/doi.org\/10.2174\/1872211312666180105114644.","journal-title":"Recent Pat Drug Deliv Formul"},{"issue":"8","key":"1409_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2217\/nnm-2016-0387","volume":"12","author":"YSR Elnaggar","year":"2017","unstructured":"Elnaggar YSR, Shehata EMM, Galal S, Abdallah OY. Self-emulsifying preconcentrates of daidzein-phospholipid complex: design, in vitro and in vivo appraisal. Nanomedicine. 2017;12(8):893\u2013910. https:\/\/doi.org\/10.2217\/nnm-2016-0387.","journal-title":"Nanomedicine"},{"issue":"4","key":"1409_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02794-z","volume":"37","author":"N Nafee","year":"2020","unstructured":"Nafee N, Gaber DM, Elzoghby AO, Helmy MW, Abdallah OY. Promoted antitumor activity of myricetin against lung carcinoma via nanoencapsulated phospholipid complex in respirable microparticles. Pharm Res. 2020;37(4):1\u201324. https:\/\/doi.org\/10.1007\/s11095-020-02794-z.","journal-title":"Pharm Res"},{"issue":"2","key":"1409_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-018-1252-4","volume":"20","author":"K Kuche","year":"2019","unstructured":"Kuche K, Bhargavi N, Dora CP, Jain S. Drug-phospholipid complex\u2014a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019;20(2):1\u201313. https:\/\/doi.org\/10.1208\/s12249-018-1252-4.","journal-title":"AAPS PharmSciTech"},{"issue":"1\u20132","key":"1409_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijpharm.2017.10.053","volume":"535","author":"MS Freag","year":"2018","unstructured":"Freag MS, Saleh WM, Abdallah OY. Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol. Int J Pharm. 2018;535(1\u20132):18\u201326. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.10.053.","journal-title":"Int J Pharm"},{"issue":"3","key":"1409_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.matpr.2016.02.019","volume":"3","author":"W Maryana","year":"2016","unstructured":"Maryana W, Rachmawati H, Mudhakir D. Formation of phytosome containing silymarin using thin layer-hydration technique aimed for oral delivery. Mater Today Proc. 2016;3(3):855\u201366. https:\/\/doi.org\/10.1016\/j.matpr.2016.02.019.","journal-title":"Mater Today Proc"},{"issue":"3","key":"1409_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","volume":"5","author":"ML Briuglia","year":"2015","unstructured":"Briuglia ML, Rotella C, McFarlane A, Lamprou DA. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 2015;5(3):231\u201342. https:\/\/doi.org\/10.1007\/s13346-015-0220-8.","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"1409_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.apsb.2019.02.010","volume":"9","author":"H Wu","year":"2019","unstructured":"Wu H, et al. Cholesterol-tuned liposomal membrane rigidity directs tumor penetration and anti-tumor effect. Acta Pharm Sin B. 2019;9(4):858\u201370. https:\/\/doi.org\/10.1016\/j.apsb.2019.02.010.","journal-title":"Acta Pharm Sin B"},{"key":"1409_CR27","doi-asserted-by":"publisher","unstructured":"Farzaneh H, Nik ME, Mashreghi M, Saberi Z, Jaafari MR, Teymouri M. \u201cA study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: from liposomal preparation to therapy\u201d. Int J Pharm. 2018;551(1\u20132):300\u2013308. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.09.047.","DOI":"10.1016\/j.ijpharm.2018.09.047"},{"key":"1409_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.fct.2018.01.017","volume":"113","author":"S Kaddah","year":"2018","unstructured":"Kaddah S, Khreich N, Kaddah F, Charcosset C, Greige-Gerges H. Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem Toxicol. 2018;113:40\u20138. https:\/\/doi.org\/10.1016\/j.fct.2018.01.017.","journal-title":"Food Chem Toxicol"},{"key":"1409_CR29","doi-asserted-by":"publisher","unstructured":"Emami J, Rezazadeh M, Varshosaz J, Aslani A. \u201cFormulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel\u202f: a detailed study of preparation, freeze drying condition, and In Vitro Cytotoxicity\". J Nanomater. 2012. https:\/\/doi.org\/10.1155\/2012\/358782.","DOI":"10.1155\/2012\/358782"},{"issue":"1","key":"1409_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jsps.2013.01.003","volume":"22","author":"AA Radwan","year":"2014","unstructured":"Radwan AA, Alanazi FK. Targeting cancer using cholesterol conjugates. Saudi Pharm J. 2014;22(1):3\u201316. https:\/\/doi.org\/10.1016\/j.jsps.2013.01.003.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"1409_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/1061186X.2016.1172589","volume":"25","author":"D Dheer","year":"2016","unstructured":"Dheer D, Arora D, Jaglan S, Rawal RK, Shankar R. Polysaccharides based nanomaterials for targeted anti-cancer drug delivery. J Drug Target. 2016;25(1):1\u201316. https:\/\/doi.org\/10.3109\/1061186X.2016.1172589.","journal-title":"J Drug Target"},{"issue":"1","key":"1409_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/1061186X.2016.1172589","volume":"25","author":"D Dheer","year":"2017","unstructured":"Dheer D, Arora D, Jaglan S, Rawal RK, Shankar R. Polysaccharides based nanomaterials for targeted anti-cancer drug delivery. J Drug Target. 2017;25(1):1\u201316. https:\/\/doi.org\/10.3109\/1061186X.2016.1172589.","journal-title":"J Drug Target"},{"issue":"11","key":"1409_CR33","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.bbamem.2011.07.026","volume":"1808","author":"S Riedl","year":"2011","unstructured":"Riedl S, et al. In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta - Biomembr. 2011;1808(11):2638\u201345. https:\/\/doi.org\/10.1016\/j.bbamem.2011.07.026.","journal-title":"Biochim Biophys Acta - Biomembr"},{"issue":"20","key":"1409_CR34","doi-asserted-by":"publisher","first-page":"9214","DOI":"10.7150\/thno.45125","volume":"10","author":"W Chang","year":"2020","unstructured":"Chang W, Fa H, Xiao D, Wang J. Targeting phosphatidylserine for cancer therapy: prospects and challenges. Theranostics. 2020;10(20):9214\u201329. https:\/\/doi.org\/10.7150\/thno.45125.","journal-title":"Theranostics"},{"key":"1409_CR35","doi-asserted-by":"publisher","unstructured":"Kaynak A, Davis HW, Kogan AB, Lee JH, Narmoneva DA, Qi X. \u201cPhosphatidylserine: The unique dual-role biomarker for cancer imaging and therapy\u201d. Cancers (Basel). 2022;14:10. https:\/\/doi.org\/10.3390\/cancers14102536.","DOI":"10.3390\/cancers14102536"},{"key":"1409_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.carbpol.2018.01.095","volume":"188","author":"MS Freag","year":"2018","unstructured":"Freag MS, Saleh WM, Abdallah OY. Laminated chitosan-based composite sponges for transmucosal delivery of novel protamine-decorated tripterine phytosomes: ex-vivo mucopenetration and in-vivo pharmacokinetic assessments. Carbohydr Polym. 2018;188:108\u201320. https:\/\/doi.org\/10.1016\/j.carbpol.2018.01.095.","journal-title":"Carbohydr Polym"},{"key":"1409_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jpba.2015.05.017","volume":"114","author":"K Zhang","year":"2015","unstructured":"Zhang K, et al. Preparation and evaluation of kaempferol-phospholipid complex for pharmacokinetics and bioavailability in SD rats. J Pharm Biomed Anal. 2015;114:168\u201375. https:\/\/doi.org\/10.1016\/j.jpba.2015.05.017.","journal-title":"J Pharm Biomed Anal"},{"key":"1409_CR38","doi-asserted-by":"publisher","unstructured":"Pawar A, Singh S, Rajalakshmi S, Shaikh K, Bothiraja C. \u201cDevelopment of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting\u201d. Artif Cells Nanomedicine Biotechnol. 2018:1\u201315. https:\/\/doi.org\/10.1080\/21691401.2018.1423991.","DOI":"10.1080\/21691401.2018.1423991"},{"issue":"3","key":"1409_CR39","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3109\/10717544.2014.936988","volume":"23","author":"R Khatik","year":"2016","unstructured":"Khatik R, et al. Development, characterization and toxicological evaluations of phospholipids complexes of curcumin for effective drug delivery in cancer chemotherapy. Drug Deliv. 2016;23(3):1067\u201378. https:\/\/doi.org\/10.3109\/10717544.2014.936988.","journal-title":"Drug Deliv"},{"key":"1409_CR40","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijbiomac.2016.01.082","volume":"86","author":"P Ghosh","year":"2016","unstructured":"Ghosh P, Roy AS, Chaudhury S, Jana SK, Chaudhury K, Dasgupta S. Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity. Int J Biol Macromol. 2016;86:408\u201317. https:\/\/doi.org\/10.1016\/j.ijbiomac.2016.01.082.","journal-title":"Int J Biol Macromol"},{"key":"1409_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jconrel.2015.10.020","volume":"220","author":"W Li","year":"2015","unstructured":"Li W, et al. Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer. J Control Release. 2015;220:107\u201318. https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.020.","journal-title":"J Control Release"},{"key":"1409_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpb.2018.04.023","volume":"128","author":"SA Sabra","year":"2018","unstructured":"Sabra SA, et al. Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer. Eur J Pharm Biopharm. 2018;128:156\u201369. https:\/\/doi.org\/10.1016\/j.ejpb.2018.04.023.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"1409_CR43","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.biomaterials.2012.10.034","volume":"34","author":"Y-C Chen","year":"2013","unstructured":"Chen Y-C, Lo C-L, Lin Y-F, Hsiue G-H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials. 2013;34(4):1115\u201327.","journal-title":"Biomaterials"},{"issue":"3","key":"1409_CR44","first-page":"683","volume":"53","author":"AO Docea","year":"2012","unstructured":"Docea AO, Mitru\u0163 P, Grigore D, Pirici D, C\u01celina DC, Gofi\u0163\u01ce E. Immunohistochemical expression of TGF beta (TGF-\u03b2), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Rom J Morphol Embryol. 2012;53(3):683\u201392.","journal-title":"Rom J Morphol Embryol"},{"issue":"5","key":"1409_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4297\/najms.2011.3227","volume":"3","author":"R Singhai","year":"2011","unstructured":"Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci. 2011;3(5):227\u201333. https:\/\/doi.org\/10.4297\/najms.2011.3227.","journal-title":"N Am J Med Sci"},{"key":"1409_CR46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s11671-018-2737-5","volume":"13","author":"T Liu","year":"2018","unstructured":"Liu T, et al. Preparation of glycyrrhetinic acid liposomes using lyophilization monophase solution method: preformulation, optimization, and in vitro evaluation. Nanoscale Res Lett. 2018;13:324. https:\/\/doi.org\/10.1186\/s11671-018-2737-5.","journal-title":"Nanoscale Res Lett"},{"issue":"March","key":"1409_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.omtn.2017.10.019","volume":"10","author":"M De","year":"2018","unstructured":"De M, et al. A novel therapeutic strategy for cancer using phosphatidylserine targeting stearylamine-bearing cationic liposomes. Mol Ther - Nucleic Acids. 2018;10(March):9\u201327. https:\/\/doi.org\/10.1016\/j.omtn.2017.10.019.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"1409_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eurpolymj.2020.110129","volume":"142","author":"M Tavares","year":"2021","unstructured":"Tavares M, et al. The use of TPGS in drug delivery systems to overcome biological barriers. Eur Polym J. 2021;142:110\u201329. https:\/\/doi.org\/10.1016\/j.eurpolymj.2020.110129.","journal-title":"Eur Polym J"},{"issue":"3","key":"1409_CR49","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13346-019-00631-4","volume":"9","author":"Z Hussain","year":"2019","unstructured":"Hussain Z, Khan S, Imran M, Sohail M, Shah SWA, de Matas M. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. Drug Deliv Transl Res. 2019;9(3):721\u201334. https:\/\/doi.org\/10.1007\/s13346-019-00631-4.","journal-title":"Drug Deliv Transl Res"},{"key":"1409_CR50","doi-asserted-by":"publisher","unstructured":"Etman SM, Abdallah OY, Mehanna RA, Elnaggar YS. \u201cLactoferrin\/hyaluronic acid double-coated lignosulfonate nanoparticles of quinacrine as a controlled release biodegradable nanomedicine targeting pancreatic cancer\u201d. Int J Pharm. 2020;578:119097. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119097.","DOI":"10.1016\/j.ijpharm.2020.119097"},{"key":"1409_CR51","doi-asserted-by":"crossref","unstructured":"Freag MS, Elnaggar YS, Abdelmonsif DA, Abdallah OY. \u201cLayer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycin\u201d.\u00a0Nanomedicine.\u00a02016;11(22):2975\u20132996.","DOI":"10.2217\/nnm-2016-0236"},{"issue":"18","key":"1409_CR52","doi-asserted-by":"publisher","first-page":"16922","DOI":"10.1021\/acsami.9b02529","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen S, et al. Fabrication and characterization of layer-by-layer composite nanoparticles based on zein and hyaluronic acid for codelivery of curcumin and quercetagetin. ACS Appl Mater Interfaces. 2019;11(18):16922\u201333. https:\/\/doi.org\/10.1021\/acsami.9b02529.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"36","key":"1409_CR53","doi-asserted-by":"publisher","first-page":"23437","DOI":"10.1021\/acsami.6b04179","volume":"8","author":"S Pulakkat","year":"2016","unstructured":"Pulakkat S, Balaji SA, Rangarajan A, Raichur AM. Surface engineered protein nanoparticles with hyaluronic acid based multilayers for targeted delivery of anticancer agents. ACS Appl Mater Interfaces. 2016;8(36):23437\u201349. https:\/\/doi.org\/10.1021\/acsami.6b04179.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1409_CR54","doi-asserted-by":"publisher","unstructured":"Hudiyanti D, Al Khafiz MF, Anam K, Siahaan P, Suyati L. \u201cAssessing encapsulation of curcumin in cocoliposome: in vitro study\u201d. Open Chem. 2021;19(1):358\u2013366. https:\/\/doi.org\/10.1515\/chem-2021-0036.","DOI":"10.1515\/chem-2021-0036"},{"issue":"1","key":"1409_CR55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10973-011-1759-3","volume":"108","author":"D Singh","year":"2012","unstructured":"Singh D, Rawat MSM, Semalty A, Semalty M. Emodin-phospholipid complex: a potential of herbal drug in the novel drug delivery system. J Therm Anal Calorim. 2012;108(1):289\u201398. https:\/\/doi.org\/10.1007\/s10973-011-1759-3.","journal-title":"J Therm Anal Calorim"},{"issue":"3","key":"1409_CR56","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s13346-020-00833-1","volume":"11","author":"HMK Ebada","year":"2021","unstructured":"Ebada HMK, Nasra MMA, Elnaggar YSR, Abdallah OY. Novel rhein\u2013phospholipid complex targeting skin diseases: development, in vitro, ex vivo, and in vivo studies. Drug Deliv Transl Res. 2021;11(3):1107\u201318. https:\/\/doi.org\/10.1007\/s13346-020-00833-1.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"1409_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymthe.2022.02.001","volume":"30","author":"H Muramatsu","year":"2022","unstructured":"Muramatsu H, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30(5):1\u201311. https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.001.","journal-title":"Mol Ther"},{"key":"1409_CR58","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2147\/IJN.S45231","volume":"8","author":"MS Freag","year":"2013","unstructured":"Freag MS, Elnaggar YSR, Abdallah OY. Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine. 2013;8:2385\u201397. https:\/\/doi.org\/10.2147\/IJN.S45231.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"1409_CR59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/cancers12020278","volume":"12","author":"E Gaio","year":"2020","unstructured":"Gaio E, Conte C, Esposito D, Reddi E, Quaglia F, Moret F. CD44 targeting mediated by polymeric nanoparticles and combination of chlorine TPCS2a-PDT and docetaxel-chemotherapy for effcient killing of breast di erentiated and stem cancer cells in vitro. Cancers (Basel). 2020;12(2):278\u201394.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"1409_CR60","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1039\/d0nr00434k","volume":"12","author":"Z Gao","year":"2020","unstructured":"Gao Z, et al. A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer. Nanoscale. 2020;12(15):8139\u201346. https:\/\/doi.org\/10.1039\/d0nr00434k.","journal-title":"Nanoscale"},{"issue":"33","key":"1409_CR61","doi-asserted-by":"publisher","first-page":"34375","DOI":"10.18632\/oncotarget.6045","volume":"6","author":"SD Vallabhapurapu","year":"2015","unstructured":"Vallabhapurapu SD, et al. Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium. Oncotarget. 2015;6(33):34375\u201388. https:\/\/doi.org\/10.18632\/oncotarget.6045.","journal-title":"Oncotarget"},{"issue":"1","key":"1409_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2014.03.043","volume":"183","author":"L Zhang","year":"2014","unstructured":"Zhang L, Zhou H, Belzile O, Thorpe P, Zhao D. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. J Control Release. 2014;183(1):114\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2014.03.043.","journal-title":"J Control Release"},{"issue":"2","key":"1409_CR63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1166\/jbn.2017.2338","volume":"13","author":"CH Chuang","year":"2017","unstructured":"Chuang CH, et al. Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy. J Biomed Nanotechnol. 2017;13(2):192\u2013203. https:\/\/doi.org\/10.1166\/jbn.2017.2338.","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"1409_CR64","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1080\/10717544.2017.1406561","volume":"24","author":"S Tan","year":"2017","unstructured":"Tan S, Zou C, Zhang W, Yin M, Gao X, Tang Q. Recent developments ind-a-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy. Drug Deliv. 2017;24(1):1831\u201342. https:\/\/doi.org\/10.1080\/10717544.2017.1406561.","journal-title":"Drug Deliv"},{"issue":"8","key":"1409_CR65","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/jphp.13126","volume":"71","author":"N Li","year":"2019","unstructured":"Li N, et al. Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells. J Pharm Pharmacol. 2019;71(8):1243\u201354. https:\/\/doi.org\/10.1111\/jphp.13126.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"1409_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12060544","volume":"12","author":"M Wang","year":"2020","unstructured":"Wang M, et al. Development and evaluation of docetaxel-phospholipid complex loaded self-microemulsifying drug delivery system: optimization and in vitro\/ex vivo studies. Pharmaceutics. 2020;12(6):1\u201319. https:\/\/doi.org\/10.3390\/pharmaceutics12060544.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1409_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-23669-9","volume":"8","author":"S Mishra","year":"2018","unstructured":"Mishra S, et al. Subcutaneous ehrlich ascites carcinoma mice model for studying cancer-induced cardiomyopathy. Sci Rep. 2018;8(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-018-23669-9.","journal-title":"Sci Rep"},{"key":"1409_CR68","doi-asserted-by":"publisher","unstructured":"Shahriari M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M. \u201cSynthesis of hyaluronic acid-based polymersomes for doxorubicin delivery to metastatic breast cancer\u201d. Int J Pharm. 2019;572:118835. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118835.","DOI":"10.1016\/j.ijpharm.2019.118835"},{"issue":"3","key":"1409_CR69","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/17425247.2020.1727442","volume":"17","author":"M Gautam","year":"2020","unstructured":"Gautam M, et al. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy. Expert Opin Drug Deliv. 2020;17(3):423\u201334. https:\/\/doi.org\/10.1080\/17425247.2020.1727442.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"1409_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-016-0708-2","volume":"18","author":"MJ Gray","year":"2016","unstructured":"Gray MJ, et al. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res. 2016;18(1):1\u201314. https:\/\/doi.org\/10.1186\/s13058-016-0708-2.","journal-title":"Breast Cancer Res"},{"key":"1409_CR71","doi-asserted-by":"publisher","unstructured":"Chen YY, et al.\u00a0\u201cBPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy\u201d. Transl Oncol. 2021;14(1):100897. https:\/\/doi.org\/10.1016\/j.tranon.2020.100897.","DOI":"10.1016\/j.tranon.2020.100897"},{"issue":"1","key":"1409_CR72","first-page":"699","volume":"17","author":"S Liu","year":"2018","unstructured":"Liu S, Chen S, Zeng J. TGF-\u03b2 signaling: a complex role in tumorigenesis. Mol Med Rep. 2018;17(1):699\u2013704.","journal-title":"Mol Med Rep"},{"issue":"8","key":"1409_CR73","doi-asserted-by":"publisher","first-page":"12173","DOI":"10.1002\/jcp.27955","volume":"234","author":"A Ahmadi","year":"2019","unstructured":"Ahmadi A, Najafi M, Farhood B, Mortezaee K. Transforming growth factor-\u03b2 signaling: tumorigenesis and targeting for cancer therapy. J Cell Physiol. 2019;234(8):12173\u201387.","journal-title":"J Cell Physiol"},{"issue":"8","key":"1409_CR74","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2217\/fon.09.90","volume":"5","author":"MK Wendt","year":"2009","unstructured":"Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial\u2013mesenchymal transition by TGF-\u03b2. Futur Oncol. 2009;5(8):1145\u201368.","journal-title":"Futur Oncol"},{"issue":"3","key":"1409_CR75","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-010-1147-x","volume":"128","author":"E Wiercinska","year":"2011","unstructured":"Wiercinska E, Naber HPH, Pardali E, van der Pluijm G, van Dam H, Ten Dijke P. The TGF-\u03b2\/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. 2011;128(3):657\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1409_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00441-011-1225-3","volume":"347","author":"X Zu","year":"2012","unstructured":"Zu X, et al. Transforming growth factor-\u03b2 signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res. 2012;347(1):73\u201384.","journal-title":"Cell Tissue Res"},{"issue":"1","key":"1409_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-12-26","volume":"12","author":"LR Gomes","year":"2012","unstructured":"Gomes LR, Terra LF, Wailemann RAM, Labriola L, Sogayar MC. TGF-\u03b21 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1\/2 in highly invasive breast cancer cells. BMC Cancer. 2012;12(1):1\u201315.","journal-title":"BMC Cancer"},{"issue":"1","key":"1409_CR78","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2011.01.023","volume":"405","author":"MG Binker","year":"2011","unstructured":"Binker MG, Binker-Cosen AA, Gaisano HY, de Cosen RH, Cosen-Binker LI. TGF-\u03b21 increases invasiveness of SW1990 cells through Rac1\/ROS\/NF-\u03baB\/IL-6\/MMP-2. Biochem Biophys Res Commun. 2011;405(1):140\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2011.01.023.","journal-title":"Biochem Biophys Res Commun"},{"key":"1409_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117454","volume":"248","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-\u03b21 signaling. Life Sci. 2020;248:117454.","journal-title":"Life Sci"},{"issue":"8","key":"1409_CR80","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00262-020-02542-7","volume":"69","author":"Q Liu","year":"2020","unstructured":"Liu Q, et al. Combined blockade of TGf-\u03b21 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunol Immunother. 2020;69(8):1477\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"1409_CR81","doi-asserted-by":"publisher","unstructured":"Owyong M,\u00a0et al.\u00a0\u201cMMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy\u201d. Life Sci Alliance. 2019;2(6). https:\/\/doi.org\/10.26508\/lsa.201800226.","DOI":"10.26508\/lsa.201800226"},{"key":"1409_CR82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.phymed.2018.09.172","volume":"50","author":"S-J Kim","year":"2018","unstructured":"Kim S-J, Pham T-H, Bak Y, Ryu H-W, Oh S-R, Yoon D-Y. Orientin inhibits invasion by suppressing MMP-9 and IL-8 expression via the PKC\u03b1\/ERK\/AP-1\/STAT3-mediated signaling pathways in TPA-treated MCF-7 breast cancer cells. Phytomedicine. 2018;50:35\u201342.","journal-title":"Phytomedicine"},{"issue":"1","key":"1409_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6374-x","volume":"19","author":"L Huang","year":"2019","unstructured":"Huang L, Lin H, Chen Q, Yu L, Bai D. MPPa-PDT suppresses breast tumor migration\/invasion by inhibiting Akt-NF-\u03baB-dependent MMP-9 expression via ROS. BMC Cancer. 2019;19(1):1\u201311.","journal-title":"BMC Cancer"},{"key":"1409_CR84","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejphar.2015.06.038","volume":"764","author":"EM Noh","year":"2015","unstructured":"Noh EM, et al. Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC\/ROS\/MAPK pathways. Eur J Pharmacol. 2015;764:79\u201386. https:\/\/doi.org\/10.1016\/j.ejphar.2015.06.038.","journal-title":"Eur J Pharmacol"},{"key":"1409_CR85","doi-asserted-by":"publisher","unstructured":"Talaat SM, Elnaggar YS, El-Ganainy SO, Gowayed MA, Abdel-Bary A, Abdallah OY. \u201cNovel bio-inspired lipid nanoparticles for improving the anti-tumoral efficacy of fisetin against breast cancer\u201d. Int J Pharm. 2022;628. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122184.","DOI":"10.1016\/j.ijpharm.2022.122184"},{"issue":"1","key":"1409_CR86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3892\/or.2017.5676","volume":"38","author":"XF Liu","year":"2017","unstructured":"Liu XF, Long HJ, Miao XY, Liu GL, Yao HL. Fisetin inhibits liver cancer growth in a mouse model: relation to dopamine receptor. Oncol Rep. 2017;38(1):53\u201362. https:\/\/doi.org\/10.3892\/or.2017.5676.","journal-title":"Oncol Rep"},{"key":"1409_CR87","doi-asserted-by":"publisher","unstructured":"Hu LF,\u00a0et al.\u00a0\u201cOral flavonoid fisetin treatment protects against prolonged high-fat-diet-induced cardiac dysfunction by regulation of multicombined signaling\u201d. J Nutr Biochem. 2020;77:108253. https:\/\/doi.org\/10.1016\/j.jnutbio.2019.108253.","DOI":"10.1016\/j.jnutbio.2019.108253"},{"issue":"6","key":"1409_CR88","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/cdd.2016.11","volume":"23","author":"RB Birge","year":"2016","unstructured":"Birge RB, et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016;23(6):962\u201378. https:\/\/doi.org\/10.1038\/cdd.2016.11.","journal-title":"Cell Death Differ"},{"issue":"2","key":"1409_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm5020013","volume":"5","author":"Y Wu","year":"2016","unstructured":"Wu Y, Sarkissyan M, Vadgama JV. Epithelial-mesenchymal transition and breast cancer. J Clin Med. 2016;5(2):1\u201318. https:\/\/doi.org\/10.3390\/jcm5020013.","journal-title":"J Clin Med"},{"key":"1409_CR90","doi-asserted-by":"publisher","unstructured":"Li J, et al.\u00a0\u201cFisetin inhibited growth and metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via PTEN\/Akt\/GSK3\u03b2 signal pathway\u201d. Front Pharmacol. 2018;9. https:\/\/doi.org\/10.3389\/fphar.2018.00772.","DOI":"10.3389\/fphar.2018.00772"},{"issue":"10","key":"1409_CR91","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cells8101118","volume":"8","author":"C-Y Loh","year":"2019","unstructured":"Loh C-Y, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.","journal-title":"Cells"},{"issue":"3","key":"1409_CR92","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/path.4728","volume":"239","author":"TM Fung","year":"2016","unstructured":"Fung TM, et al. Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK\u2013MAPK\u2013ETV4\u2013MMP\u2013E-cadherin deregulation. J Pathol. 2016;239(3):309\u201319. https:\/\/doi.org\/10.1002\/path.4728.","journal-title":"J Pathol"},{"issue":"8","key":"1409_CR93","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10585-007-9104-8","volume":"24","author":"O De Wever","year":"2007","unstructured":"De Wever O, et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis. 2007;24(8):685\u201397. https:\/\/doi.org\/10.1007\/s10585-007-9104-8.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"1409_CR94","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7150\/jca.49641","volume":"12","author":"T Chen","year":"2020","unstructured":"Chen T, et al. MUC 15 promotes osteosarcoma cell proliferation, migration and invasion through livin, MMP-2\/MMP-9 and Wnt\/\u03b2-catenin signal pathway. J Cancer. 2020;12(2):467\u201373. https:\/\/doi.org\/10.7150\/jca.49641.","journal-title":"J Cancer"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01409-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01409-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01409-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T15:31:51Z","timestamp":1704209511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01409-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01409-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"assertion":[{"value":"1 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures conducted in this work were performed in accordance with the ethical committee of Pharos University in Alexandria, Egypt (Approval No.: PUA01202006283015) complying with ARRIVE guidelines and the National Institute of Health for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}